---
title: "What The FDA Has Said About Exosomes, And When | RMA"
description: "A dated record of FDA's public statements on exosome products, from the December 6, 2019 notification to warning letters in 2026, in FDA's own words."
url: "https://regenmedacademy.com/what-the-fda-has-said-about-exosomes/"
site: "Regen Med Academy"
author: "Oscar Tellez"
published: "2026-11-18T10:00:00-05:00"
modified: "2026-11-18T10:00:00-05:00"
---

# What has the FDA said about exosomes, and when?

- [Oscar Tellez](https://regenmedacademy.com/oscar-tellez/)
- November 18, 2026

![Fda statements on exosomes: a shelf of closed archive boxes with blank spines, one pulled forward under a lamp](https://regenmedacademy.com/wp-content/uploads/2026/10/what-the-fda-has-said-about-exosomes.webp)

*Written by [Oscar Tellez](https://regenmedacademy.com/oscar-tellez/), founder of Regen Med Academy. Oscar is not a clinician. This post is education for licensed providers and is not medical advice. Last updated October 7, 2026.*

FDA has said the same thing about exosomes since December 6, 2019. On that day it wrote, “[There are currently no FDA-approved exosome products](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products).” It also said that exosomes used for diseases and conditions in people are regulated as drugs and biological products. Those are the FDA rules on exosome therapy as the agency states them. We found no FDA page or letter that departs from them when we looked on October 5, 2026, and this post lists each one by date.

## What are the FDA rules on exosome therapy for medical providers?

We did not find a special FDA rule written just for exosomes. What we found is FDA applying the rules it already has for drugs and biological products, and saying so in public more than once.

Across the record below, FDA makes three points.

- There are no FDA-approved exosome products.
- Exosome products meant for diseases or conditions in people are regulated as drugs and biological products, so they need FDA’s review and approval.
- Before approval, FDA says such a product may be given to people only in research under an IND, which is short for Investigational New Drug application.

Do you want the yes or no answer for your own clinic? It is in our post on [whether exosome products are legal to use in a clinic](https://regenmedacademy.com/are-exosome-products-legal-in-my-clinic/). This post is the record behind that answer. It gives dates and documents in FDA’s words, and it names no company.

One note on our method. We opened every page below on fda.gov on October 5, 2026. Where FDA shows a date for when the content was current, we give it.

## What did FDA say on December 6, 2019?

The first page is titled [Public Safety Notification on Exosome Products](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products). It is dated December 6, 2019, and FDA wrote it to inform “the public, especially patients, health care practitioners, and clinics.”

Why then? FDA said it had “multiple recent reports of serious adverse events experienced by patients in Nebraska who were treated with unapproved products marketed as containing exosomes.” It said the reports came to it from the Centers for Disease Control and Prevention, among others.

Two sentences in the notice carry the legal status. The first is seven words long: “There are currently no FDA-approved exosome products.”

The second is longer. “As a general matter, exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food Drug and Cosmetic Act and are subject to premarket review and approval requirements.” In plain words, FDA named the two federal laws it leans on. It said these products need review and approval before they are sold.

The notice also asked for something. It asks health care professionals and consumers to “report any adverse events related to exosome products or any other unapproved product” to FDA’s MedWatch program. It told patients to ask whether FDA has reviewed the treatment, and to ask for the IND number.

The date FDA shows for the page’s content is still December 6, 2019, and the page is still up.

## What did the safety alert of December 9, 2019 add?

Three days later, FDA posted the same message in a second place. The page is titled [Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products](https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-products). It is marked as posted on December 9, 2019.

This page sits with FDA’s MedWatch alerts, and it uses four fixed headings: audience, issue, background and recommendation. The audience line reads, “Health Professional, Patient, Consumer, Risk Manager.”

Did it change the status? No. It carries the same two status sentences, and it links back to the December 6 notice. What you should look at is the audience line, because health professionals are the first group it names.

## What does the July 22, 2020 consumer alert say?

The next page is the [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). The date at the top is July 22, 2020, and the page we opened was current as of April 9, 2024.

It has three short sentences on exosomes, one after another. “Exosome products are also regulated by FDA.” “As a general matter, exosome products intended to treat diseases or conditions in humans require FDA approval.” “There are currently no FDA-approved exosome products.”

Put the middle sentence next to the one from 2019. The 2019 notice spoke of exosomes “used to treat” diseases and conditions. The 2020 alert speaks of products “intended to treat” them, and it says they “require FDA approval.” The wording moved a little, and the position did not move at all.

We cannot tell you what FDA changed on this page between 2020 and 2024, because the page does not say. We can tell you the three exosome sentences are on it today.

There is one caution about this page. It also has a sentence about which stem cell products are approved, and the page is from April 2024. For what is approved today, use FDA’s live list, which comes up later in this post.

## What does the June 3, 2021 patient and consumer page say?

The fourth page is [Important Patient and Consumer Information About Regenerative Medicine Therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). It is dated June 3, 2021, and the page we opened was current as of April 8, 2024. It lists the unapproved products it covers, and the list ends with exosomes. Then it says, “Before approval, these products require FDA oversight in a clinical trial.”

Another sentence on the page is about selling. “These products require FDA licensure/approval to be marketed to consumers.”

This is also the page where FDA says who it has told. FDA writes that it “has repeatedly notified manufacturers, clinics, and health care practitioners of the need for Investigational New Drug applications (INDs) to legally administer these products.” Clinics are on that list, and so are the people who work in them.

The page speaks to two sales lines as well. One is a listing in the clinicaltrials.gov database, and the other is a firm that has registered with FDA. The page says neither one means “the product is legally marketed.”

One more line on this FDA page is written to patients, and your patients can read it. “Please know that if you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally.” It is on the [same patient page](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies).

## What did FDA tell practitioners on November 17, 2022?

On November 17, 2022, FDA’s biologics center held an online session for providers. The subject was how FDA oversees regenerative medicine products. FDA’s [event page](https://www.fda.gov/news-events/information-practitioners-fdas-regulatory-oversight-regenerative-medicine-products-11172022) was current as of February 17, 2023, and FDA posted a [transcript](https://www.fda.gov/media/165501/download).

A transcript is spoken remarks. It is not a rule, and it is not a guidance document. It is still FDA speaking straight to providers, so it belongs in the record.

The speaker on exosomes was an official from the center’s compliance office. Three sentences from the transcript belong here.

- “Exosomes are regulated by FDA.”
- “To be clear, as a general matter, exosome products intended to treat diseases or conditions in humans require FDA approval.”
- “There are currently no FDA-approved exosome products, and exosome products may only be distributed to participating investigators and/or administered to humans if a sponsor has an Investigational New Drug application in effect, an IND.”

The third sentence is the most direct line in this record about giving a product to a person. It ties that act to an IND that is in effect.

The same speaker took up the claim that exosome products are 361 products, and said it “is not correct.” We quote that passage in the post on exosome products in a clinic. The rule behind it is in our post on [the 351 and 361 framework](https://regenmedacademy.com/351-vs-361-hctp-rules/).

## What is in an FDA exosome warning letter?

A warning letter is FDA writing to one firm about what it found. FDA’s [page about warning letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters) says, “When FDA identifies what it believes are significant violation(s) of federal requirement(s), FDA notifies the appropriate party.” It adds, “This notification is often in the form of a Warning Letter.”

FDA posts these letters in a public [warning letter database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters). On October 5, 2026, we searched fda.gov and opened nine warning letters in which FDA writes about exosome products. We name none of the firms. These are the dates on the nine letters.

- June 4, 2020
- November 9, 2022
- September 1, 2023
- December 30, 2024
- May 5, 2025
- August 15, 2025
- September 24, 2025
- February 11, 2026
- August 14, 2026

That is what we opened. It is not a full count, and we do not know how many letters exist.

So what do the letters say? The status language is close to 2019. Take the letter dated November 9, 2022. It says, “None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them.”

The letter dated February 11, 2026 shows how little the wording has moved. FDA wrote about exosomes “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans.” It said they are subject to the rules for drugs and biological products, “including applicable premarket review and approval requirements.”

The next sentence in that letter begins, “We also direct your attention to FDA’s Public Safety Notification on Exosome Products.” So in 2026, FDA was still pointing a firm back to its 2019 page.

The letters also show where FDA looks. All nine cite the firm’s own website, and at least three also cite social media pages. Here is what I see when I read letters like these. “Every time I see someone get a warning letter, the first thing I do is I review it. In most of the letters I read, the company’s own marketing language is part of the evidence.”

Read every letter with FDA’s own caution in mind. The database page says matters in a letter “may have been subject to subsequent interaction between FDA and the letter recipient.” It says that interaction “may have changed the regulatory status of issues discussed in the letter.” So a letter shows what FDA said on one date, and it does not show how the matter ended.

## What is an untitled letter, and are there any about exosomes?

FDA also sends a lighter kind of letter. Its [page on untitled letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/issuance-untitled-letters) says they “are used for violations that may not meet the threshold of regulatory significance for a warning letter.”

FDA’s biologics center posts [a list of these letters](https://www.fda.gov/vaccines-blood-biologics/enforcement-actions-cber/bimoteam-biologicsinternet-surveillanceother), and the list we opened was current as of July 15, 2026. We opened two letters from that list that name exosome products. One is dated April 10, 2020, and the other is dated May 22, 2023.

The 2023 letter puts the status in one long sentence. It begins, “Please be advised that, as a general matter, exosome products intended to treat diseases or conditions in humans are also regulated as drugs.” It ends with the words “premarket review and approval requirements described above.”

Again, those two are what we opened, and they are not a full count.

## What has not changed as of October 5, 2026?

Here is the short list, with the date on each page.

- The December 6, 2019 notice is still posted, and it still says there are no FDA-approved exosome products.
- The consumer alert carries the same sentence, and its content was current as of April 9, 2024.
- FDA’s [list of approved cellular and gene therapy products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products) was current as of September 17, 2026, and no exosome product appears on it.
- The newest warning letter we opened that discusses exosome products is dated August 14, 2026.
- We found no FDA page that says an exosome product is approved. We found no FDA page that says an exosome product may be given to patients outside an IND.

That is almost seven years of the same position. Anything FDA posted after October 5, 2026 is not in this post, so open the pages yourself.

## What does this record not tell you?

A record like this has edges, and you should know where they are.

It is not a count of every FDA action. We listed the letters we opened, and FDA may have sent others.

It does not tell you about the one product a rep is showing you. A status page speaks about a whole category. For one product, the question is still whether an IND is in effect and whether you are named in it.

Most of these documents are about products meant for diseases or conditions. Topical and cosmetic wording raises its own question, and the post on exosome products in a clinic takes it up.

It does not tell you what your state board thinks. State law in this field changes, sometimes more than once a year. Our reading of each state, with its sources and the date we checked, is on the [rules by state page](https://regenmedacademy.com/regenerative-medicine-laws-by-state/). It is a starting point, not legal advice, and state law does not override the federal status described here.

And a notice, an alert or a letter is not the law itself. The law is in the two acts FDA names and in the rules under them. These documents show how FDA reads that law.

## How should a provider read the FDA record on exosomes?

Read it by date, by kind of document, and in FDA’s own words.

Start with the date. Each FDA page in this post shows a line that says when its content was current. Write that date next to anything you copy.

Next, look at what kind of document you are holding. A notice and a consumer alert speak to the public. A warning letter speaks to one firm on one date, and a rule is the law. They do not carry the same weight, and a sales pitch can blur them together.

Then read FDA’s words, and not a summary of them. That includes this post, which is why we link each page so you can check us.

Let’s say a rep tells you FDA has changed its position on exosomes. What do you ask? You ask for the FDA page and the date on it. If what comes back is a slide, a news story or a brochure, you do not have an FDA document yet.

Last, keep a copy. Save each page as a file on the day you read it, and put the date in the file name. FDA’s pages change, and a dated copy shows which version you read.

## Where does Regen Med Academy stand on exosomes?

Regen Med Academy is an education company. We sell education and nothing else, which means we do not sell a device or a biologic.

We approach exosomes as a subject to learn. Our exosome course is online, it is education only, and it is wait list only. You can [join the exosome wait list](https://regenmedacademy.com/contact/?course=exosomes-wait-list).

The rules have their own course with us. Our free FDA legal foundations mini course takes about 45 minutes, it is self-paced, and it has five lessons.

We cannot tell you where your own license stands, because the authority on your own scope is your licensing board, not us.

## Frequently asked questions

### Has FDA approved any exosome product since 2019?

Not that we could find. We opened FDA’s list of approved cellular and gene therapy products on October 5, 2026. The page was current as of September 17, 2026, and no exosome product was on it. The list changes, so open it on the day you need it and search the page for the word exosome.

### Is an FDA public safety notification a law?

No. It is a public statement of FDA’s position. The law is in the two acts the notice names, and in the rules under them. One is the Public Health Service Act, and the other is the Federal Food, Drug, and Cosmetic Act. The notice tells you how FDA applies those laws to exosome products, and FDA has repeated it in letters since.

### What is the difference between a warning letter and an untitled letter?

An untitled letter leaves out the warning. FDA says it “does not include a statement that warns the individual or firm that failure to promptly correct the violation may result in enforcement action.” FDA posts both kinds of letter, and both show what FDA wrote to one firm on one date.

### Where can I read the FDA exosome warning letters myself?

They are in FDA’s warning letter database, which is linked above. The database has a search box, and it has filters for the issuing office and the letter date. We did not link single letters, because we name no company in this post. The dates in our list will help you find each one.

### Does a newer date on an FDA page mean FDA changed its position?

No. The date tells you when FDA says the content was current, and it does not tell you what changed. The consumer alert is a good example. It is dated July 22, 2020, it was current as of April 9, 2024, and its exosome sentences match what FDA said in 2019. Read the words first, and then read the date.

### Can I give these FDA pages to my patients?

Yes. They are public pages, and two of them, the consumer alert and the patient page, were written for patients and consumers. Hand over the page itself and not your own summary of it. Do not add a line about what an exosome product would do for the patient.

## Key takeaways

- On December 6, 2019, FDA wrote that there are no FDA-approved exosome products. That sentence is still posted.
- FDA says exosome products meant for diseases or conditions in people are regulated as drugs and biological products.
- The consumer alert from July 2020 and the patient page from June 2021 repeat that status. Both were current as of April 2024.
- In November 2022, an FDA official told providers that exosome products may be given to people only when an IND is in effect.
- We opened nine FDA warning letters that discuss exosome products. They are dated from June 4, 2020 to August 14, 2026.
- As of October 5, 2026, no exosome product was on FDA’s list of approved cellular and gene therapy products.
- Read the record by date, by kind of document, and in FDA’s own words.

## RMA disclosure

Regenerative Medicine Academy (RMA) is an education company. We train licensed providers in some of the techniques this post covers. This post is education only. It is not medical, legal, business, tax or financial advice.

Nothing in this post is advice to use an exosome product. We researched it on October 5, 2026, and FDA’s pages may have changed since then.

## Your next step

Open the December 6, 2019 notification and FDA’s list of approved products, and save a dated copy of each. Then read our post that asks [are exosome products legal to use in my clinic](https://regenmedacademy.com/are-exosome-products-legal-in-my-clinic/) for the direct answer. After that, [get the free FDA course](https://regenmedacademy.com/fda-legal-foundations-of-regenerative-medicine/), and join the wait list for our online exosome course if you want the full subject.

The course that goes with this post

### FDA Legal Foundations of Regenerative Medicine

The FDA rules behind this field, in a short, self-paced course. It costs nothing.

[Get the free course](https://regenmedacademy.com/fda-legal-foundations-of-regenerative-medicine/#free-course)

[Or see all courses](https://regenmedacademy.com/our-courses/)

Regen Med Academy is an education company. Everything on this site is education for licensed providers, not medical or legal advice, not a treatment recommendation, and not an offer to treat. Before you offer a procedure in your state, talk to your own legal counsel and your licensing board.

[PrevPreviousHow do I explain PRP to a patient without making a claim?](https://regenmedacademy.com/how-to-explain-prp-to-a-patient/)

#### Table of Contents

Prefer our take? Star us in Google.

## More from the blog

[Nov 17, 2026By Oscar Tellez ### How do I explain PRP to a patient without making a claim? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/how-to-explain-prp-to-a-patient/)[Nov 16, 2026By Oscar Tellez ### What should a physician look for in a PRP course? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/what-physicians-should-look-for-in-a-prp-course/)[Nov 13, 2026By Oscar Tellez ### What is plasma gel bio-filler, and is it a dermal filler? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/what-is-plasma-gel-bio-filler/)

```json
{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/regenmedacademy.com\/#organization","name":"Regen Med Academy","sameAs":["https:\/\/www.facebook.com\/regenmedacademy\/","https:\/\/www.instagram.com\/regenmedacademy\/","https:\/\/www.linkedin.com\/company\/regenerative-medicine-academy-usa\/"],"logo":{"@type":"ImageObject","@id":"https:\/\/regenmedacademy.com\/#logo","url":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/08\/rma-logo-short.png","contentUrl":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/08\/rma-logo-short.png","caption":"Regen Med Academy","inLanguage":"en-US","width":"964","height":"160"}},{"@type":"BreadcrumbList","@id":"https:\/\/regenmedacademy.com\/what-the-fda-has-said-about-exosomes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/regenmedacademy.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/regenmedacademy.com\/our-blogs\/","name":"Blogs"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/regenmedacademy.com\/category\/regulatory\/","name":"Regulatory"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/regenmedacademy.com\/what-the-fda-has-said-about-exosomes\/","name":"What has the FDA said about exosomes, and when?"}}]},{"@type":"WebPage","@id":"https:\/\/regenmedacademy.com\/what-the-fda-has-said-about-exosomes\/#webpage","url":"https:\/\/regenmedacademy.com\/what-the-fda-has-said-about-exosomes\/","name":"What The FDA Has Said About Exosomes, And When | RMA","datePublished":"2026-11-18T10:00:00-05:00","dateModified":"2026-11-18T10:00:00-05:00","isPartOf":{"@id":"https:\/\/regenmedacademy.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/10\/what-the-fda-has-said-about-exosomes.webp"},"inLanguage":"en-US","breadcrumb":{"@id":"https:\/\/regenmedacademy.com\/what-the-fda-has-said-about-exosomes\/#breadcrumb"}},{"@type":"Person","@id":"https:\/\/regenmedacademy.com\/oscar-tellez\/","name":"Oscar Tellez","url":"https:\/\/regenmedacademy.com\/oscar-tellez\/","image":{"@type":"ImageObject","@id":"https:\/\/regenmedacademy.com\/wp-content\/litespeed\/avatar\/b825d4341c372553b72ec46678d94981.jpg?ver=1790899329","url":"https:\/\/regenmedacademy.com\/wp-content\/litespeed\/avatar\/b825d4341c372553b72ec46678d94981.jpg?ver=1790899329","caption":"Oscar Tellez","inLanguage":"en-US"},"sameAs":["https:\/\/regenmedacademy.com\/oscar-tellez\/"],"worksFor":{"@id":"https:\/\/regenmedacademy.com\/#organization"}},{"@type":"BlogPosting","headline":"What The FDA Has Said About Exosomes, And When | RMA","keywords":"fda rules on exosome therapy","datePublished":"2026-11-18T10:00:00-05:00","dateModified":"2026-11-18T10:00:00-05:00","articleSection":"Regulatory","author":{"@id":"https:\/\/regenmedacademy.com\/oscar-tellez\/","name":"Oscar Tellez"},"publisher":{"@id":"https:\/\/regenmedacademy.com\/#organization"},"description":"A dated record of FDA&#039;s public statements on exosome products, from the December 6, 2019 notification to warning letters in 2026, in FDA&#039;s own words.","name":"What The FDA Has Said About Exosomes, And When | RMA","@id":"https:\/\/regenmedacademy.com\/what-the-fda-has-said-about-exosomes\/#richSnippet","isPartOf":{"@id":"https:\/\/regenmedacademy.com\/what-the-fda-has-said-about-exosomes\/#webpage"},"image":{"@id":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/10\/what-the-fda-has-said-about-exosomes.webp"},"inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/regenmedacademy.com\/what-the-fda-has-said-about-exosomes\/#webpage"}}]}
```
